FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295083870> ?p ?o ?g. }

• W4295083870 endingPage "5688" @default.
• W4295083870 startingPage "5688" @default.
• W4295083870 abstract "Toxicity and resistance to newly synthesized anticancer drugs represent a challenging phenomenon of intensified concern arising from variation in drug targets and consequently the prevalence of the latter concern requires further research. The current research reports the design, synthesis, and anticancer activity of new 1,2,3-triazole-coumarin-glycosyl hybrids and their 1,2,4-triazole thioglycosides as well as acyclic analogs. The cytotoxic activity of the synthesized products was studied against a panel of human cancer cell lines. Compounds 8, 10, 16 and 21 resulted in higher activities against different human cancer cells. The impact of the hybrid derivative 10 upon different apoptotic protein markers, including cytochrome c, Bcl-2, Bax, and caspase-7 along with its effect on the cell cycle was investigated. It revealed a mitochondria-apoptotic effect on MCF-7 cells and had the ability to upregulate pro-apoptotic Bax protein and downregulate anti-apoptotic Bcl-2 protein and thus implies the apoptotic fate of the cells. Furthermore, the inhibitory activities against EGFR, VEGFR-2 and CDK-2/cyclin A2 kinases for 8, 10 and 21 were studied to detect the mechanism of their high potency. The coumarin-triazole-glycosyl hybrids 8 and 10 illustrated excellent broad inhibitory activity (IC50= 0.22 ± 0.01, 0.93 ± 0.42 and 0.24 ± 0.20 μM, respectively, for compound 8), (IC50 = 0.12 ± 0.50, 0.79 ± 0.14 and 0.15± 0. 60 μM, respectively, for compound 10), in comparison with the reference drugs, erlotinib, sorafenib and roscovitine (IC50 = 0.18 ± 0.05, 1.58 ± 0.11 and 0.46 ± 0.30 μM, respectively). In addition, the docking study was simulated to afford better rationalization and put insight into the binding affinity between the promising derivatives and their targeted enzymes and that might be used as an optimum lead for further modification in the anticancer field." @default.
• W4295083870 created "2022-09-10" @default.
• W4295083870 creator A5015834816 @default.
• W4295083870 creator A5057583383 @default.
• W4295083870 creator A5068325258 @default.
• W4295083870 creator A5069682913 @default.
• W4295083870 creator A5071725160 @default.
• W4295083870 creator A5079748080 @default.
• W4295083870 date "2022-09-03" @default.
• W4295083870 modified "2023-10-12" @default.
• W4295083870 title "New 1,2,3-Triazole-Coumarin-Glycoside Hybrids and Their 1,2,4-Triazolyl Thioglycoside Analogs Targeting Mitochondria Apoptotic Pathway: Synthesis, Anticancer Activity and Docking Simulation" @default.
• W4295083870 cites W109492528 @default.
• W4295083870 cites W1121361470 @default.
• W4295083870 cites W1966669615 @default.
• W4295083870 cites W1966696534 @default.
• W4295083870 cites W1972739162 @default.
• W4295083870 cites W1983350693 @default.
• W4295083870 cites W1983971746 @default.
• W4295083870 cites W1994027923 @default.
• W4295083870 cites W2025565532 @default.
• W4295083870 cites W2043759232 @default.
• W4295083870 cites W2069361214 @default.
• W4295083870 cites W2082653928 @default.
• W4295083870 cites W2082841583 @default.
• W4295083870 cites W2089655089 @default.
• W4295083870 cites W2092449831 @default.
• W4295083870 cites W2114712929 @default.
• W4295083870 cites W2143238584 @default.
• W4295083870 cites W2143536404 @default.
• W4295083870 cites W2162624029 @default.
• W4295083870 cites W2166573361 @default.
• W4295083870 cites W2795353688 @default.
• W4295083870 cites W2896563358 @default.
• W4295083870 cites W2907712775 @default.
• W4295083870 cites W2909349197 @default.
• W4295083870 cites W2912378698 @default.
• W4295083870 cites W2921227021 @default.
• W4295083870 cites W2960049296 @default.
• W4295083870 cites W2980949303 @default.
• W4295083870 cites W2981028192 @default.
• W4295083870 cites W2990308106 @default.
• W4295083870 cites W3022360542 @default.
• W4295083870 cites W3025286256 @default.
• W4295083870 cites W3034999189 @default.
• W4295083870 cites W3037163993 @default.
• W4295083870 cites W3038925944 @default.
• W4295083870 cites W3043487380 @default.
• W4295083870 cites W3049253240 @default.
• W4295083870 cites W3115988672 @default.
• W4295083870 cites W3125885528 @default.
• W4295083870 cites W3147142721 @default.
• W4295083870 cites W3147444719 @default.
• W4295083870 cites W3157900784 @default.
• W4295083870 cites W3159435427 @default.
• W4295083870 cites W3170695023 @default.
• W4295083870 cites W3183072679 @default.
• W4295083870 cites W3189110082 @default.
• W4295083870 cites W3193344206 @default.
• W4295083870 cites W3196777249 @default.
• W4295083870 cites W3215995278 @default.
• W4295083870 cites W4200492933 @default.
• W4295083870 cites W4213033615 @default.
• W4295083870 cites W4223550910 @default.
• W4295083870 cites W4225726287 @default.
• W4295083870 cites W4281740290 @default.
• W4295083870 cites W4282933028 @default.
• W4295083870 doi "https://doi.org/10.3390/molecules27175688" @default.
• W4295083870 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36080455" @default.
• W4295083870 hasPublicationYear "2022" @default.
• W4295083870 type Work @default.
• W4295083870 citedByCount "7" @default.
• W4295083870 countsByYear W42950838702023 @default.
• W4295083870 crossrefType "journal-article" @default.
• W4295083870 hasAuthorship W4295083870A5015834816 @default.
• W4295083870 hasAuthorship W4295083870A5057583383 @default.
• W4295083870 hasAuthorship W4295083870A5068325258 @default.
• W4295083870 hasAuthorship W4295083870A5069682913 @default.
• W4295083870 hasAuthorship W4295083870A5071725160 @default.
• W4295083870 hasAuthorship W4295083870A5079748080 @default.
• W4295083870 hasBestOaLocation W42950838701 @default.
• W4295083870 hasConcept C121608353 @default.
• W4295083870 hasConcept C124320809 @default.
• W4295083870 hasConcept C159110408 @default.
• W4295083870 hasConcept C170493617 @default.
• W4295083870 hasConcept C184235292 @default.
• W4295083870 hasConcept C185592680 @default.
• W4295083870 hasConcept C190283241 @default.
• W4295083870 hasConcept C2778087573 @default.
• W4295083870 hasConcept C2779438470 @default.
• W4295083870 hasConcept C29537977 @default.
• W4295083870 hasConcept C41685203 @default.
• W4295083870 hasConcept C502942594 @default.
• W4295083870 hasConcept C54355233 @default.
• W4295083870 hasConcept C55493867 @default.
• W4295083870 hasConcept C71924100 @default.
• W4295083870 hasConcept C86803240 @default.
• W4295083870 hasConcept C96232424 @default.
• W4295083870 hasConcept C98274493 @default.

• next